Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach-Reference-Cited by-同舟云学术

Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach

Published:2018-09-10 Issue:10 Volume:13 Page:2862-2867
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Bassi Zuni I.¹^ORCID,Fillmore Martin C.²,Miah Afjal H.¹,Chapman Trevor D.³,Maller Claire³,Roberts Emma J.³,Davis Lauren C.³,Lewis Darcy E.³,Galwey Nicholas W.⁴,Waddington Kirsty E.,Parravicini Valentino,Macmillan-Jones Abigail L.¹,Gongora Celine⁵,Humphreys Philip G.³^ORCID,Churcher Ian^ORCID,Prinjha Rab K.³,Tough David F.³

Affiliation:

1. Protein Degradation DPU, Future Pipelines Discovery, GlaxoSmithKline, Medicines Research Centre, Stevenage SG1 2NY, United Kingdom

2. NCE-MD Medicinal Chemistry UK Team, R&D Platform Technology & Science, GlaxoSmithKline, Medicines Research Centre, Stevenage SG1 2NY, United Kingdom

3. Epigenetics DPU, Immuno-Inflammation and Oncology Therapy Area, GlaxoSmithKline, Medicines Research Centre, Stevenage SG1 2NY, United Kingdom

4. Target Sciences Statistics, R&D Target Sciences, GlaxoSmithKline, Medicines Research Centre, Stevenage SG1 2NY, United Kingdom

5. Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier F-34298, France

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acschembio.8b00705

Reference21 articles.

1. Bromodomain: an acetyl-lysine binding domain

2. Clinical progress and pharmacology of small molecule bromodomain inhibitors